BOSTON and SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a...
PDUFA target action date of November 14, 2026 Potential first FDA-approved treatment option for the acute treatment of agitation associated...
Axsome obtains exclusive global rights to balipodect, a potentially first-in-class selective phosphodiesterase 10A inhibitor Acquisition further expands Axsome’s industry-leading CNS...
Investment accelerates U.S. rollout of a scalable, at-home brain neuromodulation therapy for patients with depression and inadequate response to at least...
Teva’s biosimilar, PONLIMSI™, is now FDA-approved across all indications of the reference product, Prolia® (denosumab), to treat a variety of...
Johnson & Johnson presents findings from the largest European real-world dataset for esketamine nasal spray (NS) which confirm its effectiveness...
sNDA submitted seeking approval of IGALMI® in the at-home (outpatient) setting for the treatment of acute agitation associated with bipolar...
NORTH CHICAGO, Ill., March 26, 2026 /PRNewswire/ -- Rosalind Franklin University announced today that Paige Arneson-Wissink, PhD, assistant professor of...
The academic health system curated insights from more than 300 health care leaders to fuel publication of "NEXT Intelligence: A...
Supplier agreement expands access for physician practices to AI-driven tools for proactive brain healthBOSTON, March 26, 2026 /PRNewswire/ -- Linus...
Aims to improve quality of care for patients with Alzheimer's disease… Exploring adoption of Neurophet's key solutionsCollaboration expected to leverage...
A New AI System Embedded Inside a Healthcare Network Answers Questions in Real Time, Bridging Electronic Medical Records and Clinician...
Firefly’s AI-powered, FDA-cleared EEG/ERP Technology is Being Deployed to Support Assessment and Treatment of PTSD and TBI in U.S. Service...
Firefly’s AI-powered, FDA-cleared EEG/ERP Technology is Being Deployed to Support Assessment and Treatment of PTSD and TBI in U.S. Service...
BURLINGTON, Mass. and JERUSALEM, March 26, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...
BURLINGTON, Mass. and JERUSALEM, March 26, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...
Phase 2 ZEPHYR trial of ML-007C-MA for schizophrenia expected to reach target enrollment (n=300) in April 2026, with topline results...
BETHESDA, Md., March 26, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology...
PRECISE-AD Phase 1b trial fully enrolled. Completion of six-month assessments expected in Q2 2026 with blinded interim analysis anticipated early...
NEW DELHI, March 25, 2026 /PRNewswire/ -- According to the in-depth study published by MarkNtel Advisors, the Global Artificial Intelligence (AI)...